December 08, 2025 21:04 ET | Source: InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed…
November 26, 2025 19:00 ET | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27,…
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breakerScemblix…
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic…